Swedish companies are increasingly investing in R&D. In 2023, the corporate sector's expenditure on its own R&D amounted to 166.1 billion Swedish kronor ($14.8 billion), an increase of 14.4 billion kronor or 9.4% compared to 2021 (in constant prices).
The investments corresponded to 2.68% of gross domestic product (GDP) and this places Sweden at the top among European Union (EU) countries in terms of business research intensity, according to a posting on the website of the country’s pharma trade group Lif.
With the exception of 2021, Swedish companies have been the most R&D-intensive in the EU over the past decade.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze